Page last updated: 2024-12-10

prostaglandin g2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5280883
CHEBI ID27647
SCHEMBL ID16782384
MeSH IDM0115343

Synonyms (27)

Synonym
(5z,9s,11r,13e,15s)-15-hydroperoxy-9,11-epidioxyprosta-5,13-dien-1-oic acid
(5z)-7-{(1r,4s,5r,6r)-6-[(1e,3s)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid
CHEBI:27647
LMFA03010009
9s,11r-epidioxy-15s-hydroperoxy-5z,13e-prostadienoic acid
51982-36-6
prostaglandin g2
C05956
pgg2
DB03866
pgg(2)
unii-az87dud2y8
az87dud2y8 ,
prosta-5,13-dien-1-oic acid, 9,11-epidioxy-15-hydroperoxy-, (5z,9alpha,11alpha,13e,15s)-
(5z)-7-[(1r,4s,5r,6r)-6-[(1e,3s)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
gtpl5245
endoperoxide g2
SCHEMBL16782384
SGUKUZOVHSFKPH-YNNPMVKQSA-N
9,11-epidioxy-15-hydroperoxy-prosta-5,13-dien-1-oate
9,11-epidioxy-15-hydroperoxy-prosta-5,13-dien-1-oic acid
(z)-7-[(1r,4s,5r,6r)-6-[(e,3s)-3-hydroperoxyoct-1-enyl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
9s,11r-epidioxy-15s-hydroperoxy-5z,13e-prostadienoate
Q19835971
(5z)-7-((1r,4s,5r,6r)-6-((1e,3s)-3-hydroperoxy-1-octen-1-yl)-2,3-dioxabicyclo(2.2.1)hept-5-yl)-5-heptenoic acid
(5z,9.alpha.,11.alpha.,13e,15s)-9,11-epidioxy-15-hydroperoxyprosta-5,13-dien-1-oic acid
DTXSID00866229
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins G
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (64)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Nicotinate metabolism2243
Nicotinamide salvaging1030
Biological oxidations150276
Phase I - Functionalization of compounds69175
COX reactions17
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Metabolism of alpha-linolenic acid615
Eicosanoid metabolism via cyclooxygenases (COX)137
Prostaglandin and leukotriene metabolism in senescence619
Quercetin and Nf-kB / AP-1 induced apoptosis09
Folic acid network070
Eicosanoid lipid synthesis map17
Quercetin and Nf-kB / AP-1 induced cell apoptosis09
Selenium micronutrient network095
Eicosanoid synthesis026
Arachidonic acid metabolism pathway011
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (44.90)18.7374
1990's9 (18.37)18.2507
2000's15 (30.61)29.6817
2010's3 (6.12)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.61 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index41.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.04%)5.53%
Reviews6 (12.24%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]